AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Heart Failure (HF) is a multi-faceted and life-threatening syndrome characterized by
significant morbidity and mortality, poor functional capacity and quality of life, and high costs …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Accompanying the aging of populations worldwide, and increased survival with chronic
diseases, the incidence and prevalence of atrial fibrillation (AF) are rising, justifying the term …

Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of 64
million people globally. Although the incidence of HF has stabilised worldwide and seems to …

Background: Even on optimal therapy, many patients with heart failure and atrial fibrillation
experience cardiovascular complications. Additional treatments are needed to reduce these …

Background Paroxysmal and permanent atrial fibrillation (AF) are common in heart failure
with preserved ejection fraction (HFpEF). Objectives This study sought to determine the …

The Japanese Circulation Society (JCS) published the “Guidelines for Pharmacological
Treatment of Arrhythmia” in 2004, and a revised edition was published in 2009. 1 Both …

Objectives: This study assessed sex-related differences in a large cohort of unselected
patients with heart failure (HF) across the ejection fraction (EF) spectrum. Background …